Novartis Ag

Other

Eric Vangrevelinghe

Hank Michael James Petrassi

Rainer Machauer

Badry Bursulaya

Nikolaus Johannes Stiefl

James Paul Lajiness

Thomas Ullrich

Henri Mattes

Philipp Janser

Anette Von Matt

Peggy Usselmann

Catherine Fooks Solovay

Juraj Velcicky

Angela Mackay

Nina Gommermann

Christopher Farady

Andreas Fisch

Swapnil Malekar

Farshad Ramazani

Anne-Catherine Remond

Pascal Furet

Nichola Smith

Marc Gerspacher

Stefanie Flohr

Yves Auberson

Marina Tintelnot-Blomley

Thomas Josef Troxler

Siem Jacob Veenstra

Philipp Holzer

Oliver Simic

Christoph Gaul

Claudia Betschart

Carole Pissot Soldermann

Ralf Glatthar

Carole Pissot Sondermann

The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R, R, R, R, Rand Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

NLRP3 inflammasome inhibitors

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Aza-indazole compounds for use in tendon and/or ligament injuries

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Substituted indazoles for treating tendon and/or ligament injuries

The invention relates to 2,7-disubstituted benzoxazole and 2,4-disubstituted oxazolo[5,4-c]pyridine compounds of the formula I given below, as well as salts thereof, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, these compounds for use in the treatment (including prophylaxis) of the animal, especially human, body (especially with regard to a proliferative disease), the use thereof&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the treatment especially of a protein tyrosine kinase mediated disease (such as a tumor disease) or for the manufacture of a pharmaceutical preparation for use in the treatment of such a disease, a method for the treatment of such a disease and a pharmaceutical preparation for the treatment of a disease as mentioned. The compounds are of the formula I, wherein the symbols are as defined in the description. The compounds inhibit, for example, JAK2 and JAK3.

Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

The present invention relates to quinoxaline compound of the formula (I): wherein

Quinoxaline derivatives as tyrosine kinase activity inhibitors

The present invention pertains to novel dibenzo[b,f]oxepine-10-carboxamides compound to a process for the preparation of such compounds of formula I, their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula I.

Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof

Growing community of inventors

Saint-Louis, France

Eric Vangrevelinghe